Cervical cancer screening in developing countries:: Why is it ineffective?: The case of Mexico

被引:106
作者
Lazcano-Ponce, EC
Moss, S
de Ruíz, PA
Castro, JS
Avila, MH
机构
[1] Inst Nacl Salud Publ, Ctr Invest Salud Poblac, Cuernavaca 62508, Morelos, Mexico
[2] Inst Canc Res, Epidemiol Sect, Canc Screening Evaluat Unit, Surrey, England
[3] Univ Nacl Autonoma Mexico, Gen Hosp, Unidad Patol, Mexico City 04510, DF, Mexico
[4] Inst Mexicano Seguro Social, Ctr Med Nacl Siglo XXI, Unidad Invest Med Epidemiol & Serv Salud, Mexico City, DF, Mexico
关键词
screening; quality; cervical cancer; Pap test; women's health;
D O I
10.1016/S0188-0128(99)00006-8
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Mexico established a national cervical cancer-screening program in 1974, Despite the implementation of the program, there was a steady mortality trend of 16 per 100,000 women over 15 years. Methods. A diagnostic procedure of the pitfalls was applied to the following steps of the screening procedure: Pap sampling quality; cytological diagnosis validity; compliance of women; and determinants of non-participation. Results. The low effectiveness of screening on cervical cancer is principally due to factors associated with quality and coverage. Pap quality is deficient; 64% of a random sample of specimens lacked endocervical cells. Reading centers presented false negative indices of between 10 and 54%. Women seek screening in a late stage of disease (55% with cervical cancer seek care because they have symptoms). Tn addition, coverage is low; in women between 15 and 49 years of age in Mexico City, 64.2% have a history of Pap, compared with 30% in rural areas. Knowledge of what the Pap is used for strongly determines the use of screening. In rural areas, only 40% of women are informed about the purpose of the Pap test. Conclusions. A proposal to reorganize Mexico's screening program includes the following five main strategies: (a) increased coverage; (b) improved quality control of how cervical smears are taken; (c) better interpretation of Pap tests: (d) guaranteed treatment for those whose tests show abnormalities, and (e) improved follow-up. (C) 1999 IMSS, Published by Elsevier Science Inc.
引用
收藏
页码:240 / 250
页数:11
相关论文
共 74 条
  • [1] Alonso De Ruiz P., 1996, Boletin de la Oficina Sanitaria Panamericana, V121, P518
  • [2] ALONSO P, 1995, COMPENDIUM QUALITY A, P115
  • [3] ORGANIZATION AND RESULTS OF THE CERVICAL CYTOLOGY SCREENING-PROGRAM IN BRITISH-COLUMBIA, 1955-85
    ANDERSON, GH
    BOYES, DA
    BENEDET, JL
    LERICHE, JC
    MATISIC, JP
    SUEN, KC
    WORTH, AJ
    MILLNER, A
    BENNETT, OM
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1988, 296 (6627): : 975 - 978
  • [4] [Anonymous], 1993, ANAL QUANT CYTOL, V15, P358
  • [5] [Anonymous], 1986, BMJ-BRIT MED J, V293, P659
  • [6] CANCER PREVENTION IN PRIMARY-CARE - SCREENING FOR CERVICAL-CANCER .7.
    AUSTOKER, J
    [J]. BRITISH MEDICAL JOURNAL, 1994, 309 (6949) : 241 - 248
  • [7] AVILA MH, 1998, INT J EPIDEMIOL, V27, P370
  • [8] Surveillance for equity in cervical cytology screening
    Bailie, RS
    Bourne, D
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1996, 25 (01) : 46 - 52
  • [9] BERAL V, 1994, CANCER SURV, V20, P265
  • [10] Automated screening of cervical cytology specimens
    Birdsong, GG
    [J]. HUMAN PATHOLOGY, 1996, 27 (05) : 468 - 481